FDA Approves Pomalyst For Advanced Multiple Myeloma

The Food and Drug Administration Feb. 8 approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

Multiple myeloma is a form of blood cancer that primarily affects older adults and arises from plasma cells in the bone marrow, the agency said.

Pomalyst is a pill that modulates the body’s immune system to destroy cancerous cells and inhibit their growth, FDA said. It is intended for patients who have received at least two prior therapies, including lenalidomide and bortezomib, and whose disease did not respond to treatment and progressed within 60 ...